Sulfinpyrazone did not reduce transient ischemic attack (TIA) recurrences in a short-term trial. However, avoiding early TIA recurrences significantly lowered the risk of future neurological events over two years.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: